Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)

Lex Eggermont, Marna Bouwhuis, Wim Kruit, A Testori, Timo ten Hagen, A Yver, C Xu

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)


The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) alpha-2b administered weekly in patients with lymph node-positive melanoma. Serum concentrations were analyzed to determine exposure to Peg-IFN alpha-2b. After surgery, patients were randomized to receive Peg-IFN alpha-2b or to observation only. The treatment group received 6 mu g/kg/week Peg-IFN alpha-2b subcutaneously for 8 weeks, followed by a maintenance dose of 3 mu g/kg/week for up to 5 years. Blood samples were collected between months 3 and 60. A total of 208 Peg-IFN alpha-2b concentrations from 48 patients were available. Serum trough concentrations increased in a dose-related manner. Mean dose-normalized serum concentrations and intersubject variability over the 5-year study period in patients with melanoma were similar to those observed in patients with chronic hepatitis. Data suggest that the exposure to Peg-IFN alpha-2b was sustained during long-term adjuvant treatment with Peg-IFN alpha-2b in patients with melanoma, consistent with the EORTC 18991 trial's conclusion of a significant, sustained, and relapse-free survival benefit.
Original languageUndefined/Unknown
Pages (from-to)671-677
Number of pages7
JournalCancer Chemotherapy & Pharmacology
Issue number4
Publication statusPublished - 2010

Research programs

  • EMC MM-03-47-11

Cite this